Search

Your search keyword '"Ortqvist, Eva"' showing total 8 results
Start Over Author "Ortqvist, Eva" Publisher american diabetes association
8 results on '"Ortqvist, Eva"'

1. Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis Study

Author

Delli, Ahmed J., Vaziri-Sani, Fariba, Lindblad, Bengt, Elding-Larsson, Helena, Carlsson, Annelie, Forsander, Gun, Ivarsson, Sten A., Ludvigsson, Johnny, Kockum, Ingrid, Marcus, Claude, Samuelsson, Ulf, Ortqvist, Eva, Groop, Leif, Bondinas, George P., Papadopoulos, George K., and Lernmark, Ake

Subjects
Genes -- Physiological aspects -- Research, HLA histocompatibility antigens -- Physiological aspects -- Genetic aspects -- Research, Autoantibodies -- Analysis -- Physiological aspects -- Research, Type 1 diabetes -- Diagnosis -- Genetic aspects -- Research, Histocompatibility antigens -- Physiological aspects -- Genetic aspects -- Research, Health
Abstract

We examined whether zinc transporter 8 autoantibodies (ZnT8A; arginine ZnT8-RA, tryptophan ZnT8-WA, and glutamine ZnT8-QA variants) differed between immigrant and Swedish patients due to different polymorphisms of SLC3OA8, HLA-DQ, or both. Newly diagnosed autoimmune (≥ 1 islet autoantibody) type 1 diabetic patients (n = 2,964,, More than 90% of childhood type 1 diabetes (T1D) in Caucasian populations are classified as autoimmune diabetes in association with HLA class II genes (1). The autoimmune response involves production [...]

Published
2012
Full Text
View/download PDF

2. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes

Author

Ekstrom, Klas, Salemyr, Jenny, Zachrisson, Ingmar, Carlsson-Skwirut, Christine, Ortqvist, Eva, and Bang, Peter

Subjects
Binding proteins -- Research, Insulin glargine -- Dosage and administration -- Research, Type 1 diabetes -- Drug therapy -- Research, Health, Drug therapy, Research, Dosage and administration
Abstract

OBJECTIVE--We sought to test the hypothesis that start of insulin glargine with sustained nightly insulin action results in changes in circulating concentrations of IGF-I and IGF binding proteins (IGFBPs) in [...]

Published
2007

3. Temporary preservation of β-cell function by diazoxide treatment in childhood type 1 diabetes

Author

Ortqvist, Eva, Bjork, Elisabeth, Wallensteen, Mana, Ludvigsson, Johnny, Aman, Jan, Johansson, Calle, Forsander, Gun, Lindgren, Fredrik, Berglund, Lars, Bengtsson, Mats, Berne, Christian, Persson, Bengt, and Karlsson, F. Anders

Subjects
Type 1 diabetes -- Diagnosis -- Research -- Care and treatment, Diazoxide -- Research, Diabetics -- Care and treatment, Health, Diagnosis, Care and treatment, Research
Abstract

OBJECTIVE--We examined the effect of diazoxide, an ATP-sensitive [K.sup.+] channel opener and inhibitor of insulin secretion, on β-cell function and remission in children at clinical onset of type 1 diabetes [...]

Published
2004

4. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes--specific GAD65Abs

Author

Padoa, Carolyn J., Banga, J. Paul, Madec, Anne-Marie, Ziegler, Manfred, Schlosser, Michael, Ortqvist, Eva, Kockum, Ingrid, Palmer, Jerry, Rolandsson, Olov, Binder, Katherine A., Foote, Jefferson, Luo, Dong, and Hampe, Christiane S.

Subjects
Physiological aspects, Diabetes research -- Physiological aspects, Type 1 diabetes -- Physiological aspects, Diabetes -- Research
Abstract

Type 1 diabetes is an autoimmune disease in which the insulin-secreting β-cells of the pancreas are destroyed. Circulating islet autoantibodies and autoreactive T-cells are hallmarks of this islet cell specific [...], Autoantibodies to the 65-kDa isoform of GAD (GAD65Abs) are associated with type 1 diabetes development, but the conformational nature of the GAD65Ab epitopes complicates the evaluation of disease risk. Six GAD65-specific recombinant Fabs (rFabs) were cloned from monoclonal antibodies b96.11, DP-C, DP-A, DPD, 144, and 221-442. The binding of GAD65Abs in 61 type 1 diabetic patients to GAD65 was analyzed by competitive radioimmunoassays with the six rFabs to ascertain disease-specific GAD65Ab binding specificities. The median binding was reduced significantly by rFab b96.11 (72%) (P < 0.0001), DP-A (84%) (P < 0.0001), DP-C (84%) (P < 0.0001), 221-442 (79%) (P < 0.0001), and DP-D (80%) (P < 0.0001). The competition pattern in type 1 diabetic patients differed from that in GAD65Ab-positive late autoimmune diabetes in adults (LADA) patients (n = 44), first-degree relatives (n = 38), and healthy individuals (n = 14). Whereas 87 and 72% of the type 1 diabetic sera were competed by rFab b96.11 and DP-C, respectively, only 34 and 26% of LADA patients, 18 and 25% of first-degree relatives, and 7 and 28% of healthy individuals showed competition (P < 0.0001). These findings support the view that type 1 diabetes is associated with disease- and epitope-specific GAD65Abs and supports the notion that the middle epitope is disease associated. These GAD65-specific rFabs should prove useful in predicting type 1 diabetes and in the study of conformational GAD65Ab epitopes.

Published
2003

5. Stability of Disease-Associated Antibody Titers in Pregnant Women With Type 1 Diabetes With or Without Residual β-Cell Function

Author

NOVAK, ERIK J., ORTQVIST, EVA, NORD, EVA, EDWALL, LENA, HAMPE, CHRISTIANE S., BEKRIS, LYNN, PERSSON, BENGT E., and LERNMARK, AKE

Subjects
Diabetes in pregnancy -- Physiological aspects -- Research, Comorbidity -- Research -- Physiological aspects, Type 1 diabetes -- Research -- Physiological aspects, Health, Physiological aspects, Research
Abstract

Pregnancy has wide-ranging effects on maternal metabolism and the maternal immune system to facilitate the growth of the semiallogenic fetus. Changes in the immune system appear to affect autoimmune processes, [...]

Published
2000

6. Zinc Transporter 8 Autoantibodies and Their Association With SLC30A8 and HLA-DQ Genes Differ Between Immigrant and Swedish Patients With Newly Diagnosed Type 1 Diabetes in the Better Diabetes Diagnosis Study

Author

Delli, Ahmed J, Vaziri-Sani, Fariba, Lindblad, Bengt, Elding-Larsson, Helena, Carlsson, Annelle, Forsander, Gun, Ivarsson, Sten A, Ludvigsson, Johnny, Kockum, Ingrid, Marcus, Claude, Samuelsson, Ulf, Ortqvist, Eva, Groop, Leif, P Bondinas, George, Papadopoulos, George K, Lernmark, Ake, Delli, Ahmed J, Vaziri-Sani, Fariba, Lindblad, Bengt, Elding-Larsson, Helena, Carlsson, Annelle, Forsander, Gun, Ivarsson, Sten A, Ludvigsson, Johnny, Kockum, Ingrid, Marcus, Claude, Samuelsson, Ulf, Ortqvist, Eva, Groop, Leif, P Bondinas, George, Papadopoulos, George K, and Lernmark, Ake

Abstract

We examined whether zinc transporter 8 autoantibodies (ZnT8A; arginine ZnT8-RA, tryptophan ZnT8-WA, and glutamine ZnT8-QA variants) differed between immigrant and Swedish patients due to different polymorphisms of SLC30A8, HLA-DQ, or both. Newly diagnosed autoimmune (andgt;= 1 islet autoantibody) type 1 diabetic patients (n = 2,964, andlt;18 years, 55% male) were ascertained in the Better Diabetes Diagnosis study. Two subgroups were identified: Swedes (n = 2,160, 73%) and immigrants (non-Swedes; n = 212, 7%). Non-Swedes had less frequent ZnT8-WA (38%) than Swedes (50%), consistent with a lower frequency in the non-Swedes (37%) of SLC30A8 CT+TT (RW+WW) genotypes than in the Swedes (54%). ZnT8-RA (57 and 58%, respectively) did not differ despite a higher frequency of CC (RR) genotypes in non-Swedes (63%) than Swedes (46%). We tested whether this inconsistency was due to HLA-DQ as 2/X (2/2; 2/y; y is anything but 2 or 8), which was a major genotype in non-Swedes (40%) compared with Swedes (14%). In the non-Swedes only, 2/X (2/2; 2/y) was negatively associated with ZnT8-WA and ZnT8-QA but not ZnT8-RA. Molecular simulation showed nonbinding of the relevant ZnT8-R peptide to DQ2, explaining in part a possible lack of tolerance to ZnT8-R. At diagnosis in non-Swedes, the presence of ZnT8-RA rather than ZnT8-WA was likely due to effects of HLA-DQ2 and the SLC30A8 CC (RR) genotypes., Funding Agencies|Swedish Child Diabetes Foundation (Barndiabetesfonden)||National Institutes of Health|DK-63861DK-26190|Swedish Research Council||KA Wallenberg Foundation||European Union|202013|Swedish Diabetes Association||Skane County Council Foundation for Research and Development||Swedish Association of Local Authorities and Regions||EU funds||Hellenic State funds

Published
2012
Full Text
View/download PDF

7. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes.

Author

Örtqvist E, Björk E, Wallensteen M, Ludvigsson J, Åman J, Johansson C, Forsander G, Lindgren F, Berglund L, Bengtsson M, Berne C, Persson B, Karisson FA, Ortqvist, Eva, Björk, Elisabeth, Wallensteen, Måna, Ludvigsson, Johnny, Aman, Jan, Johansson, Calle, and Forsander, Gun

Abstract

Objective: We examined the effect of diazoxide, an ATP-sensitive K(+) channel opener and inhibitor of insulin secretion, on beta-cell function and remission in children at clinical onset of type 1 diabetes.Research Design and Methods: A total of 56 subjects (21 girls and 35 boys, age 7-17 years) were randomized to 3 months of active treatment (diazoxide 5-7.5 mg/kg in divided doses) or placebo in addition to multiple daily insulin injections and were followed for 2 years.Results: Diazoxide decreased circulating C-peptide concentrations by approximately 50%. After cessation of the treatment, basal and meal-stimulated C-peptide concentrations increased to a maximum at 6 months, followed by a decline. Meal-stimulated C-peptide concentration was significantly higher at 12 months (0.43 +/- 0.22 vs. 0.31 +/- 0.26 nmol/l, P = 0.018) and tended to fall less from clinical onset to 24 months in the diazoxide- vs. placebo-treated patients (-0.05 +/- 0.24 vs. -0.18 +/- 0.26 nmol/l, P = 0.064). At 24 months, the meal-stimulated C-peptide concentrations were 0.24 +/- 0.20 and 0.20 +/- 0.17 nmol/l, respectively. Side effects of diazoxide were prevalent.Conclusions: This study demonstrates that partial inhibition of insulin secretion for 3 months at onset of childhood type 1 diabetes suspends the period of remission and temporarily preserves residual insulin production. Further evaluation of the full potential of beta-cell rest will require compounds with less side effects as well as protocols optimized for sustained secretory arrest. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

8. GAD65 antibody epitope patterns of type 1.5 diabetic patients are consistent with slow-onset autoimmune diabetes.

Author

Hampe, Christiane S., Kockum, Ingrid, Landin-Olsson, Mona, Torn, Carina, Örtqvist, Eva, Persson, Bengt, Rolandsson, Olov, Palmer, Jerry, Lernmark, Åke, Törn, Carina, Ortqvist, Eva, and Lernmark, Ake

Subjects
IMMUNOGLOBULINS, EPITOPES, DIABETES, ANTIGENS, AUTOANTIBODIES, COMPARATIVE studies, ENZYMES, TYPE 1 diabetes, ISOENZYMES, RESEARCH methodology, MEDICAL cooperation, RESEARCH, EVALUATION research
Abstract

Focuses on a study which investigated whether GAD65 antibody epitopes in type 1.5 diabetic patients differ from those found in type 1 diabetic patients and other GAD65 positive phenotypes. Methodology of the study; Results and discussion.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results